Overview

A Study to Evaluate the Safety and Efficacy of Celgosivir in Patients With Chronic Hepatitis C Genotype 1 Infection

Status:
Completed
Trial end date:
2005-08-01
Target enrollment:
Participant gender:
Summary
The objective of the study is to evaluate the safety and efficacy of celgosivir for 12 weeks in patients with chronic hepatitis C genotype 1 infection.
Phase:
Phase 2
Details
Lead Sponsor:
BioWest Therapeutics Inc